Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16987094 | 0.88 | USP2 (0.45) | USP2SMN1; SMN2DDB1CRBNHPGD | |
| SCHEMBL414000 | 0.85 | USP2 (0.45) | USP2SMN1; SMN2DDB1CRBNHPGD | |
| SCHEMBL17065177 | 0.84 | USP2 (0.46) | USP2SMN1; SMN2DDB1CRBNHPGD | |
| SCHEMBL13952744 | 0.83 | CYP4F2 (0.45) | USP2SMN1; SMN2DDB1CRBNHPGD | |
| SCHEMBL5896294 | 0.83 | USP2 (0.41) | USP2SMN1; SMN2DDB1CRBNHPGD | |
| SCHEMBL23536116 | 0.82 | USP2 (0.45) | USP2SMN1; SMN2DDB1CRBNHPGD | |
| SCHEMBL2442944 | 0.82 | USP2 (0.45) | USP2SMN1; SMN2DDB1CRBNHPGD | |
| SCHEMBL15076623 | 0.82 | USP2 (0.45) | USP2SMN1; SMN2HPGDEPHX2GPR119 | |
| SCHEMBL21388184 | 0.82 | USP2 (0.45) | USP2SMN1; SMN2DDB1CRBNHPGD | |
| SCHEMBL23070802 | 0.82 | USP2 (0.45) | USP2SMN1; SMN2DDB1CRBNHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100166819-A1 | Transforming Growth Factor Modulators | BIOGEN IDEC MA INC. A CORPORATION | 2010-07-01 | — | — | US | disclosed |
| EP-1973914-A2 | TRANSFORMING GROWTH FACTOR MODULATORS | Biogen Idec MA Inc. (US) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007076086-A2 | TRICYCLIC SPIRO COMPOUNDS USEFUL AS TRANSFORMING GROWTH FACTOR MODULATORS | BIOGEN IDEC MA INC (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100166819-A1 | Transforming Growth Factor Modulators | ACVR1, TGFBR1, ACVRL1 | USP2 4117/4885SMN1; SMN2 4638/4885DDB1 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.